UNSPSC 51161563: Zafirlukast

This classification denotes an anti-asthmatic agent with the molecular formula C31H33N3O6S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XZ629S5L50, chemically known as ici 204,219 but generally known as zafirlukast, which bears US NIH Compound Identifier 5717. European Medicines Agency schedules Zafirlukast in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00128MIG.

UNSPSC 51161563 Zafirlukast, a Commodity code, encompasses pharmaceutical products supplied through state and local cooperative purchasing agreements for distribution across participating government facilities. State and local governments procure asthma and respiratory medications like zafirlukast primarily through multistate cooperative purchasing vehicles that aggregate demand and negotiate volume pricing with pharmaceutical manufacturers, who then deliver through authorized drug wholesalers to hospitals, clinics, correctional facilities, and other public health systems. Cooperative purchasing alliances—particularly multistate groups administered by state procurement offices—are the dominant issuing body for this commodity, centralizing pharmaceutical sourcing across multiple jurisdictions and reducing acquisition costs through consolidated contracting. Individual state departments, county health agencies, and public health districts may also solicit independently, though cooperative agreements represent the primary procurement channel at the state and local level.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal on January 20, 2026 (S1070000015802) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products, with proposals due March 26, 2026. The solicitation spans participating state and local government facilities across Minnesota, Oregon, and other member jurisdictions within the MMCAP network. Manufacturers must supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—and meet cGMP certification and Drug Supply Chain Security Act compliance requirements. Awarded vendors receive placement with wholesalers by May 15, 2026, with resulting contracts effective July 1, 2026 for a two-year initial term and optional extensions. Evaluation weights price competitiveness at 75 percent, with the remaining 25 percent distributed across fixed pricing, administrative compliance, EDI capability, and agreement to a 3 percent administrative fee; no specific set-aside designations were disclosed in available documentation.